Episode 41 – A Promising New Treatment for SCID!

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk .  To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.   Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis.   Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: [email protected] ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Chow have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst